8-K: KalVista Pharmaceuticals Secures FDA Approval for EKTERLY, Bolsters Global Commercialization, and Reports Fiscal Year 2025 Financials

KalVista Pharmaceuticals announced the landmark FDA approval of EKTERLY (sebetralstat) as the first and only oral on-demand treatment for hereditary angioedema, alongside fiscal year 2025 financial results showing a strengthened cash position and new international commercialization agreements.

Summary

• Received FDA approval for EKTERLY (sebetralstat) on July 7, 2025, making it the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
• The U.S. launch of EKTERLY is currently underway.
• Six additional global regulatory submissions for sebetralstat are under review.
• Entered an exclusive licensing agreement with Kaken Pharmaceutical, Co., Ltd. for commercialization of sebetralstat in Japan, which included an upfront payment of $11 million received in June 2025, with an additional $11 million anticipated upon a regulatory milestone in early 2026, plus potential commercial milestone payments up to $2 million and royalties in the mid-twenties as a percentage of sales.
• Granted Pendopharm, a division of Pharmascience Inc., exclusive rights for regulatory approval and commercialization of sebetralstat in Canada.
• Cash, cash equivalents, and marketable securities totaled $220.6 million as of April 30, 2025, an increase from $210.4 million on April 30, 2024, providing financial runway into 2027.
• Research and development expenses decreased to $71.7 million for the fiscal year ended April 30, 2025, from $86.2 million for the fiscal year ended April 30, 2024.
• General and administrative expenses increased to $116.3 million for the fiscal year ended April 30, 2025, from $54.3 million for the fiscal year ended April 30, 2024, primarily due to pre-commercial planning expenses related to EKTERLY.
• Reported a net loss of $(183.4) million for the fiscal year ended April 30, 2025, compared to a net loss of $(126.6) million for the fiscal year ended April 30, 2024.
• Net loss per share was $(3.69) for the fiscal year ended April 30, 2025, compared to $(3.44) for the fiscal year ended April 30, 2024.

Sentiment

Score: 8

Explanation: The FDA approval of EKTERLY, its first commercial product, coupled with a strong cash position and new international licensing agreements, represents a major positive catalyst for the company, despite an expected increase in G&A expenses due to pre-commercial activities and an increased net loss.

Positives

• Received FDA approval for EKTERLY (sebetralstat), establishing it as the first and only oral on-demand treatment for hereditary angioedema (HAE).
• The U.S. launch of EKTERLY is underway, indicating active commercialization efforts.
• Secured exclusive licensing agreements for sebetralstat commercialization in Japan with Kaken Pharmaceutical and in Canada with Pendopharm, expanding global market reach.
• Received an upfront payment of $11 million from the Kaken Pharmaceutical agreement in June 2025.
• Maintained a strong cash position of $220.6 million as of April 30, 2025, providing financial runway into 2027.
• Six additional global regulatory submissions for sebetralstat are under review, indicating potential for further international market expansion.
• New clinical data presented at major medical congresses (EAACI, C1-INH, EAC) reinforced EKTERLY's efficacy and safety, demonstrating rapid and consistent symptom relief for HAE attacks.

Negatives

• Net loss increased to $(183.4) million for the fiscal year ended April 30, 2025, from $(126.6) million in the prior fiscal year.
• General and administrative expenses significantly increased to $116.3 million for fiscal year 2025, up from $54.3 million in fiscal year 2024, primarily due to pre-commercial planning for EKTERLY.
• Net loss per share worsened to $(3.69) for fiscal year 2025 from $(3.44) for fiscal year 2024.

Risks

• Actual results could differ materially from expectations due to numerous risks and uncertainties.
• Uncertainty regarding the success of efforts to commercialize EKTERLY (sebetralstat).
• Uncertainty regarding the ability to successfully obtain foreign regulatory approvals for sebetralstat.
• Uncertainty about the safety and efficacy of sebetralstat and other product candidates.
• Uncertainty regarding the timing of clinical trials and their results.
• Uncertainty regarding the ability to commence or complete ongoing clinical studies, including KONFIDENT-S and KONFIDENT-KID trials.
• Uncertainty regarding the ability of EKTERLY to treat HAE.
• Uncertainty regarding the future progress and potential success of the oral Factor XIIa program.

Future Outlook

The company expects EKTERLY to become the foundational therapy for HAE management worldwide, supported by the ongoing U.S. launch, six global regulatory submissions under review, and commercial partnerships in Japan and Canada. The current cash position provides financial runway into 2027.

Management Comments

• "The FDA approval of EKTERLY represents a major milestone—not only as the first commercial product for KalVista, but more importantly, as the first and only oral on-demand therapy for people living with HAE."
• "EKTERLY delivers a long-awaited treatment that is safe, effective, and easy to administer."
• "Our commercial team is actively engaging in the field, leveraging their expertise to educate and activate patients and physicians to enable timely access, drive awareness, and support informed treatment decisions around this important new therapy."
• "With commercial partners now in place in Canada and Japan, and six global regulatory submissions under review, we believe EKTERLY is poised to become the foundational therapy for HAE management worldwide."

Industry Context

The FDA approval of EKTERLY as the first and only oral on-demand therapy for hereditary angioedema (HAE) addresses a significant unmet need in the rare disease market. This positions KalVista as a key innovator in the HAE therapeutic space, potentially disrupting the existing treatment landscape which has largely relied on injectable or less convenient prophylactic options, by offering a novel, patient-friendly oral alternative.

Comparison to Industry Standards

• EKTERLY (sebetralstat) is highlighted as the "first and only oral on-demand treatment" for HAE, setting a new standard compared to existing injectable or prophylactic therapies.
• Clinical data from KONFIDENT-S showed a median time to beginning of symptom relief of 1.3 hours, demonstrating rapid action for an oral therapy in HAE.
• Analysis from KONFIDENT-S showed a median time to end of attack progression of 19.8 minutes, reinforcing rapid effect after absorption, which is competitive with or potentially faster than some existing on-demand treatments.
• The utility of EKTERLY in treating severe or very severe attacks, with symptom relief beginning in 1.36 hours and substantial reduction in 9.15 hours, demonstrates its broad applicability across attack severities, which is a key differentiator in the HAE treatment paradigm.

Stakeholder Impact

• Shareholders: Positive impact due to FDA approval, potential for revenue generation from EKTERLY, expanded market reach through licensing deals, and a strong cash position. Increased net loss is a short-term negative but expected for commercialization.
• Patients (HAE): Significant positive impact as EKTERLY offers the first and only oral on-demand treatment, providing a safe, effective, and easy-to-administer option for acute attacks.
• Physicians: Provides a new, convenient, and effective treatment option for managing HAE attacks in their patients.
• Employees: Positive impact due to successful product approval and commercial launch, potentially leading to company growth and stability.
• Commercial Partners (Kaken, Pendopharm): New business opportunities and potential for revenue generation through exclusive commercialization rights in their respective territories.

Next Steps

• Continue the U.S. launch of EKTERLY.
• Pursue regulatory approvals for sebetralstat in six additional global markets.
• Achieve regulatory milestone in Japan for an additional $11 million payment (anticipated early 2026).
• Continue clinical studies, including KONFIDENT-S and KONFIDENT-KID trials.
• Further develop the oral Factor XIIa program.

Key Dates

Recommendation

Keywords

KalVista Pharmaceuticals, EKTERLY, sebetralstat, hereditary angioedema, HAE, FDA approval, oral on-demand treatment, rare diseases, biopharmaceutical, financial results, fiscal year 2025, licensing agreement, Japan, Canada, Kaken Pharmaceutical, Pendopharm, cash position, R&D expenses, G&A expenses, net loss, clinical trials, KONFIDENT-S, KONFIDENT-KID, Factor XIIa